A non-surgical and long-lasting treatment to substantially reduce back pain

ended

Stayble Therapeutics AB is a Swedish life science SME developing an injectable treatment (STA-363) for chronic low back pain (cLBP) caused by spinal disc degeneration. STA-363 aims to considerably reduce the patient´s pain in the long-term. CLBP affects the lives of over 50 million people in the EU and U.S., with the total costs for society in the U.S. alone estimated at 100 B$-200 B$ (80 B€ - 160 B€), making cLBP one of the costliest and most disabling conditions globally. Over two thirds of patients with discogenic cLBP are not helped by the conservative treatment options of painkillers and physiotherapy; and only a small fraction are eligible for a spinal fusion surgery, the last line of treatment. Stayble’s patent-pending solution STA-363 offers a cost-effective disease modifying long-term treatment option to bridge this gap in available treatment options. The treatment is currently in Phase Ib clinical trial with final results expected in Q3/2018. Stayble will lead the development of STA-363 through Phase II proof of concept study, and thereafter partner with pharma companies for further development and global commercialisation. The feasibility study, performed under this SME Phase 1 project, will focus on gaining in-depth market understanding on the patient side as well taking a better look at the potential partners and partnering models. The results will strengthen and provide future innovative direction for company’s business plan and commercialization strategy.